| Name | Title | Contact Details |
|---|
Bruce Leeb and Company is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
To enhance the health and well being of our communities through the compassionate delivery of quality healthcare. An organization of caring professionals trusted as our community’s healthcare system of choice for clinical excellence.
Excelsior Medical is a privately held medical device company with a primary focus on innovative IV catheter maintenance products that may reduce infection, medication errors and healthcare costs. The company manufactures and sells SwabCap and SwabFlush for the disinfection and protection of IV needleless connectors. Formed in 1989, Excelsior also manufactures and sells prefilled saline flush syringes, prefilled heparin flush and lock syringes, and syringe pump systems.
Executive Health Exams International is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA was founded on the belief that a personalized medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. The Company`s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure. ARCA has identified common genetic variations in the cardiovascular system that it believes interact with Gencaro’s pharmacology and may predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. We believe AF is an attractive indication for Gencaro because data from BEST, the previously conducted Phase 3 heart failure trial involving Gencaro in 2,708 HF patients, suggest Gencaro may have a potentially significant effect in reducing and/or preventing AF. Based on the BEST trial, we believe Gencaro`s prevention of AF in HF patients is pharmacogenetically regulated, similar to the effects on HF clinical endpoints. GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to Toprolol-XL for prevention of symptomatic AF or atrial flutter (AFL) in patients with heart failure and/or reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB) and availability of additional financing, potentially transition the trial to a Phase 3 trial and enroll an estimated additional 420 patients. Under the collaboration with Medtronic, ARCA plans to conduct a substudy that will include continuous monitoring of the cardiac rhythms of patients enrolled during the Phase 2B portion of GENETIC-AF. These substudy patients will have heart rhythm monitoring via a Medtronic device, either a previously implanted cardiac resynchronization or defibrillation device, or a previously or newly inserted Reveal® LINQ Insertable Cardiac Monitor (ICM) System. The collaboration substudy will measure AF burden, defined as a patient’s actual time in AF regardless of symptoms. For the DSMB interim analysis, AF event rates, AF burden and components of the primary endpoint of the study, time to recurrence of symptomatic AF/AFL or death after electrical cardioversion to sinus rhythm, will be reviewed by the DSMB to determine if there is sufficient potential for a statistically significant efficacy signal in the overall Phase 2B/3 study population.